Publications by authors named "A Dosso"
It is not unusual for naturally occurring compounds to be limited for their use in cosmetics due to their low water solubility. Recently, aiming at accessing novel phlorizin (a glycosylated bioactive recovered from apple tree wood and already used in cosmetics as antioxidant ingredient) analogues, we reported the synthesis of very promising - but low water-soluble - biomass-derived chalcones (CHs) and dihydrochalcones (DHCs) exhibiting antioxidant and anti-tyrosinase activities. Glycosylating bioactive compounds being one of the most common strategies to increase their water solubility, herein we report the enzymatic glycosylation of the CHs mentioned above, as well as DHC using cyclodextrin glycosyltransferases (CGTase), enzymes well-known for catalyzing the selective α(1→4) transglycosylation.
View Article and Find Full Text PDFArticle Synopsis
- Aging leads to the buildup of proteins that behave like amyloid, but how these proteins form isn't fully understood.
- Researchers found that errors in messenger RNA cause amyloid-like proteins to be produced in various human cell types, including stem cells and neurons.
- These errors increase with DNA damage, which is commonly associated with aging, suggesting a connection between normal aging processes and age-related diseases.
Despite major therapeutic advancements in recent years, multiple myeloma (MM) remains an incurable disease with nearly all patients experiencing relapsed and refractory disease over the course of treatment. Extending the duration and durability of clinical responses will necessitate the development of therapeutics with novel targets that are capable of robustly and specifically eliminating myeloma cells. B-cell maturation antigen (BCMA) is a membrane-bound protein expressed predominantly on malignant plasma cells and has recently been the target of several novel therapeutics to treat MM patients.
View Article and Find Full Text PDFIntroduction: Multiple myeloma (MM) is an incurable bone marrow (BM)-based cancer involving clonal plasma cells. Most patients show elevated levels of serum monoclonal protein (sMP) and kappa or lambda serum free light chains (sFLCs) at diagnosis. However, around 1-2% of patients, termed nonsecretory, do not produce these biomarkers.
View Article and Find Full Text PDFArticle Synopsis
- Ruxolitinib (RUX) is an FDA-approved medication for treating conditions like myelofibrosis and polycythemia vera, and this study examines its effectiveness combined with lenalidomide (LEN) in patients with progressing multiple myeloma who previously received other treatments.
- The study involved a phase I trial where participants, after failing initial therapies, received a combination of RUX and methylprednisolone (MP), and those with disease progression were given LEN as well.
- Of the 29 participants, there was a 31% overall response rate to the initial RUX and MP treatment, with some showing varying degrees of disease stabilization, but also highlighted the challenges in managing advanced